Načítá se...
Production and characterization of no-carrier-added (161)Tb as an alternative to the clinically-applied (177)Lu for radionuclide therapy
BACKGROUND: (161)Tb is an interesting radionuclide for cancer treatment, showing similar decay characteristics and chemical behavior to clinically-employed (177)Lu. The therapeutic effect of (161)Tb, however, may be enhanced due to the co-emission of a larger number of conversion and Auger electrons...
Uloženo v:
| Vydáno v: | EJNMMI Radiopharm Chem |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6620226/ https://ncbi.nlm.nih.gov/pubmed/31659528 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41181-019-0063-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|